- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 22
- States / cities
- Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Luer lock applicator, Vial access device, Ibuprofen, Acetaminophen, Ketorolac
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 5
- States / cities
- Anaheim, California • Pasadena, California • Draper, Utah + 2 more
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Luer Lock applicator, Vial access device, aprepitant
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Surgical Bleeding
- Interventions
- Raplixa, Gelfoam, Rescue treatment
- Drug · Device
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 10 more
- Conditions
- Recurrent Medulloblastoma, Recurrent Ependymoma
- Interventions
- Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio
- Conditions
- Postoperative Pain
- Interventions
- HTX-011, Saline Placebo, Bupivacaine HCl, Luer-lock applicator, Vial access device
- Drug · Device
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 15
- States / cities
- Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 11 more